Clinical Trial Update: WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating WL276 CAR-T cell therapy targeting CD276 in patients with recurrent or progressive glioblastoma; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• WL276 CAR-T Cell Therapy

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Recurrent or Progressive Glioblastoma | EARLY_Phase 1 | Status: NOT_YET_RECRUITING